Protagonist Therapeutics (PTGX)
(Real Time Quote from BATS)
$46.69 USD
+0.77 (1.68%)
Updated Sep 20, 2024 10:26 AM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Cash flow Statements
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -78.96 | -127.39 | -125.55 | -66.15 | -77.19 |
Depreciation/Amortization & Depletion | -1.26 | 2.82 | 4.61 | 2.76 | 1.93 |
Net Change from Assets/Liabilities | -19.51 | -7.77 | -3.31 | -19.02 | 26.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 29.49 | 24.20 | 16.40 | 9.92 | 7.59 |
Net Cash From Operating Activities | -70.24 | -108.14 | -107.87 | -72.48 | -41.53 |
Property & Equipment | -0.61 | -0.80 | -1.10 | -0.47 | -0.97 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -38.65 | 92.26 | -14.76 | -90.49 | -52.74 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -39.26 | 91.47 | -15.86 | -90.97 | -53.71 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 171.25 | 19.00 | 130.11 | 258.16 | 36.27 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | -10.52 | 9.77 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.77 | -0.16 | -0.19 | -0.01 | 0.00 |
Net Cash from Financing Activities | 170.48 | 18.84 | 129.92 | 247.63 | 46.04 |
Effect of Exchange Rate Changes | 0.00 | -0.09 | -0.13 | 0.18 | -0.03 |
Net Change In Cash & Equivalents | 60.98 | 2.08 | 6.07 | 84.35 | -49.23 |
Cash at Beginning of Period | 125.97 | 123.89 | 117.82 | 33.47 | 82.69 |
Cash at End of Period | 186.95 | 125.97 | 123.89 | 117.82 | 33.47 |
Diluted Net EPS | -1.39 | -2.60 | -2.71 | -1.92 | -2.98 |
Fiscal Year End for Protagonist Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 176.72 | 207.34 | -78.96 | -106.29 | -72.19 |
Depreciation/Amortization & Depletion | -1.57 | -0.80 | -1.26 | -0.74 | -0.56 |
Net Change from Assets/Liabilities | 47.74 | -243.33 | -19.51 | -3.05 | -3.96 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 18.30 | 9.35 | 29.49 | 22.89 | 16.12 |
Net Cash From Operating Activities | 241.19 | -27.43 | -70.24 | -87.20 | -60.59 |
Property & Equipment | -0.27 | -0.24 | -0.61 | -0.59 | -0.19 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -81.78 | 6.31 | -38.65 | 22.62 | 35.77 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -82.05 | 6.07 | -39.26 | 22.03 | 35.59 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 10.37 | 7.80 | 171.25 | 170.72 | 135.40 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.60 | -0.60 | -0.77 | -0.77 | -0.77 |
Net Cash from Financing Activities | 9.77 | 7.20 | 170.48 | 169.95 | 134.64 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 168.92 | -14.16 | 60.98 | 104.78 | 109.64 |
Cash at Beginning of Period | 186.95 | 186.95 | 125.97 | 125.97 | 125.97 |
Cash at End of Period | 355.87 | 172.79 | 186.95 | 230.75 | 235.61 |
Diluted Net EPS | -0.50 | 3.26 | 0.54 | -0.58 | -0.68 |